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Abstract
Schizophrenia is a chronic psychiatric disorder the cause of which is unknown. It is considered to be a neurodevelopmental disorder that results
from an interaction of genetic and environmental factors. Direct evidence for links between schizophrenia and TRP channels is lacking. However,
several aspects of the pathophysiology of the disorder point to a possible involvement of TRP channels. In this review evidence for links between
TRP channels and schizophrenia with respect to neurodevelopment, dopaminergic and cannabinoid systems, thermoregulation, and sensory
processes, is discussed. Investigation of these links holds the prospect of a new understanding of schizophrenia with resultant therapeutic
advances.
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Schizophrenia is a chronic, debilitating psychiatric disorder
that afflicts people of all races and carries a life-time risk of the
order of 1%. It causes lifelong disability, resulting in major
individual and societal cost. Despite extensive investigation, the
cause of schizophrenia remains unknown. The complexity of the
disorder is reflected in the varying symptomatology. Classically,
the positive symptoms, which include delusions, hallucinations
and thought disorder, were considered to constitute the major
diagnostic criteria of schizophrenia. However, it is now
recognized that impaired cognition, particularly in visual
memory and working memory, and the negative symptoms of
social withdrawal, poverty of speech and anhedonia, are also
core symptoms of the disorder [1,2].
Typically the overt signs and symptoms of schizophrenia do
not manifest until early adulthood. It is now generally accepted
that it is a neurodevelopmental disorder that has its origins in the
prenatal or neonatal period, and results from an interaction of
both genetic and environmental factors. Recently, the concept
has arisen that schizophrenia might result from aberrations in the
neuroplasticity phenomena that govern normal brain develop-
ment and function [3,4]. Several genes have been implicated as⁎ Tel.: +1 61 2 49291673; fax: +1 61 2 49292461.
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O-methyltransferase (COMT), dysbindin, disrupted in schizo-
phrenia 1 (DISC1), and regulator of G-protein signaling (RGS)
protein-4 (RGS-4), the strongest evidence being for NRG1 [5].
For more detailed information on the neurobiology of schizo-
phrenia and susceptibility genes for the disorder the reader is
referred to recent reviews [6–8].
Neuropathological studies on post-mortem human brain
have shown that the brains of subjects with schizophrenia are
reduced in volume compared with those of healthy individuals
[9–11], the frontal lobe being the more severely affected of all
four lobes [10]. Furthermore, the brains of subjects with
schizophrenia have larger ventricles and thinner cortices,
particularly in the prefrontal and temporal regions, than those
of normal subjects [12,13]. Selemon et al. [14,15] made the
important observation that neuronal density was increased in the
prefrontal cortex of subjects with schizophrenia. This finding
led to the ‘reduced neuropil hypothesis’ that the symptoms of
schizophrenia result from reduced cortical connectivity rather
than a reduction in neuron numbers [16]. Reduced interneuronal
space [17], mean cell spacing abnormalities [18], and reduced
neuronal size [19] have also been found in the neocortex of
subjects with schizophrenia.
The dopamine hypothesis of schizophrenia, which dominated
the field for many years, resulted from the observation that
stimulants, such as amphetamine that act via release of dopa-
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antipsychotic efficacy of dopamine D2 receptor antagonists [21].
The roles of the three major dopamine pathways in the central
nervous system (CNS), viz. the nigrostriatal pathway projecting
from the substantia nigra to the caudate putamen associated
primarily with movement control, the mesolimbic and meso-
cortical pathways projecting from the ventral tegmental area
(VTA) to the limbic areas (nucleus accumbens and ventral
striatum) and cortex, respectively, associated with schizophrenia
and reward, and the tuberoinfundibular pathway important in the
inhibition of prolactin secretion, have been extensively inves-
tigated over the past three decades [22]. Although the classical
dopamine D2 receptor antagonists were effective in treating the
positive symptoms of schizophrenia, they produced serious
Parkinsonian-like side effects, presumably due to action on the
nigrostriatal pathway as well as on the mesolimbic and meso-
cortical pathways. Furthermore, they were relatively ineffective
in treating the negative symptoms and cognitive impairment of
the disorder. The newer atypical antipsychotic drugs have a
reduced side effect profile and some efficacy in treating the
negative symptoms, but are not effective in treating the cognitive
impairment. Thus there is an ongoing search for more ap-
propriate drug targets.
Although the antipsychotic efficacy of D2 receptor antago-
nists suggested that the symptoms of schizophrenia resulted
from a functional excess of subcortical dopamine, several lines
of evidence suggest that there might be a deficit in dopamine in
the dorsolateral prefrontal cortex in schizophrenia resulting in
impairment of working memory [23]. Since working memory is
dependent on D1 receptor signaling, there has been recent
increasing interest in the dopamine system and D1 receptors in
the human cortex [24].
Alterations in markers for several neurotransmitter systems,
including the serotonin, gamma-aminobutyric acid (GABA),
glutamate and cholinergic systems, have been found in the
brains of subjects with schizophrenia. The lack of efficacy of the
D2 receptor antagonists in treating the negative symptoms and
cognitive impairment in schizophrenia has led to exploration of
the possible roles of these other neurotransmitter systems, albeit
with the understanding that any new model will need to provide
an explanation for the involvement of dopamine. The hypoglu-
tamatergic hypothesis of schizophrenia has received consider-
able attention. This hypothesis arose from the observation that
administration of N-methyl-D-aspartate (NMDA) antagonists,
phencyclidine (PCP) and ketamine induced psychotic symptoms
and cognitive dysfunction in healthy humans [25–27]. This
hypothesis has been supported by the development of a mutant
mouse with greatly reduced levels of the NMDA receptor
subunit, NR1, which exhibited behaviours considered to be
related to schizophrenia, including hyperactivity and impaired
social behaviours, that were ameliorated by antipsychotic drugs
[28].
2. Overview of TRP channels
The transient receptor potential (TRP) superfamily of ion
channels is present throughout the animal kingdom. The mem-bers mediate flux of cations across the cell membrane resulting
in increased intracellular concentrations of Ca2+ and Na+, and
depolarization of cells. They are widely expressed in mamma-
lian tissues in both excitable and nonexcitable cells and play an
important role in cell signalling. Mammalian TRP channel
proteins are characterized by six transmembrane spanning
domains with a pore domain between the fifth and sixth domain.
The TRP domain is a homologous block of about 25 intracellular
amino acid residues adjacent to the C-terminal side of S6 that is
loosely conserved in several TRP subfamilies [29,30]. TRP
channels are subdivided into six subfamilies on the basis of
amino acid sequence homology: TRPA, TRPC, TRPM, TRPML,
TRPP and TRPV [31,32]. TRP channels and their structure–
function relationships have been reviewed recently [33]. Data
from genome sequencing projects suggest that the TRP gene
family is now complete [34].
A characteristic of TRP channels is polymodal activation.
TRP channels are variously activated by several exogenous
natural products such as capsaicin, as well as endogenous
chemicals of different structures, including endogenous lipids
or lipid metabolites (DAG, phosphoinositides, eicosanoids,
anandamide), purine nucleotides and inorganic ions (Ca2+ and
Mg2+). Thus receptors such as G-protein-coupled receptors
(GPCRs) and receptor tyrosine kinases that activate phospho-
lipase C, can modulate TRP channel activity by either
hydrolysis of phosphatidylinositol (4,5) bisphosphate (PIP2),
production of diacylglycerol (DAG), or production of inositol
(1,4,5) trisphosphate (IP3), with resultant liberation of Ca
2+
from intracellular stores [35]. TRP channels act as cellular
sensors and are directly activated by physical stimuli such as
changes in ambient temperature and mechanical stimuli [36].
Although lacking a conserved series of arginine residues in the
S4 domain that form the sensor for transmembrane electrical
potential in classical voltage gated ion channels, TRP channels
exhibit voltage–dependent current relaxation following depo-
larization which is modulated by temperature or ligand binding
[37].
The TRPC1 channel was the first TRP channel to be
identified and cloned [38]. Several TRPC channels have since
been identified and these may be divided into three groups on the
basis of sequence and functional similarities, TRPC1/4/5,
TRPC3/6/7 and TRPC2 [30]. The human TRPC2 gene encodes
a non-functional truncated protein [39]. All TRPC channels are
highly expressed in human brain with discrete patterns of
distribution [40]. The hTRPC1, hTRPC3 and hTRPC5 mRNAs
have been found widely expressed at similar levels across most
brain regions, with hTRPC5 exhibiting the most CNS-specific
expression with ten-fold higher levels in the CNS than in the
periphery [40].
The thermo-TRP channels are a subset of TRP channels
expressed in primary afferent neurons and cutaneous tissues that
respond to distinct thermal thresholds [41]. The thermo-TRP
channels include TRPV1–4 channels which are heat activated,
and TRPM8 and TRPA1 which are cold activated, the channel
phenotype being conferred by the C-terminal domain [42]. The
TRPV subfamily may be divided into two groups: TRPV1–4,
and TRPV5–6. TRPV1–4 channels are expressed in the nervous
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responding to different temperature ranges from moderate to
noxious heat. The TRPV1 channel, also known as the capsaicin
receptor or vanilloid receptor 1, was first identified in sensory
neurons [43,46], but is now known to be widely distributed in
both the central and peripheral nervous systems [47–49].
3. Possible links between TRP channels and schizophrenia
Since schizophrenia results from a disorder of the human
nervous system, aspects of TRP channel function that might
relate to brain development and function are of greatest
relevance. Currently there is lack of direct evidence linking
TRP channels to schizophrenia. Nevertheless, several aspects of
the disorder suggest that TRP channels might play direct or
indirect roles in its pathogenesis and symptomatology. In this
review possible links between TRP channels and schizophrenia
in relation to neurodevelopment, neurochemical mechanisms, in
particular dopaminergic and cannabinoid mechanisms, and
disorders of thermoregulation and sensation observed in subjects
with schizophrenia, are discussed.
3.1. TRPC channels and neurodevelopment
The reduced neuropil found in the cortex in schizophrenia has
been attributed to reduced neuronal dendritic arborization. An
important recent development of possible relevance to the
reduced neuropil found in schizophrenia has been the discovery
that TRPC channels play key roles in neurite extension and
growth cone guidance [50]. Homomeric TRPC5 channels are
rapidly delivered to the plasma membrane following growth
factor receptor stimulation [51] and have been shown to control
neurite length and growth cone morphology of cultured mouse
hippocampal neurons by regulating Ca2+ influx [50]. The
mechanisms governing the inhibitory role of TRPC5 in neuronal
outgrowth have been proposed to involve a protein complex
between neuronal calcium sensor-1 (NCS-1) protein and TRPC5
[52]. Ca2+ influx through TRPC3 channels has been shown to
control selectively growth cone guidance [53].
A diversity of TRPC heteromers has also been found in
mammalian brain, with several novel heteromers present in
developing brain. Thus it has been proposed that these novel
TRPC heteromers might play specific roles in developing brain,
particularly as voltage-dependent Ca2+ entry channels emerge
later than TRPC channels during development [54]. The
possibility that formation of particular TRPC heteromers in
developing human brain might predispose to schizophrenia is
intriguing, and offers a challenge for future investigators.
3.2. TRP channels and synaptic mechanisms
Microarray studies on human postmortem brain have shown a
reduction in transcripts encoding proteins involved in the
presynaptic release of neurotransmitters in the prefrontal cortex
in schizophrenia [55,56]. Furthermore, a study of mRNA from
single stellate entorhinal neurons microdissected from post-
mortem human brain revealed a reduction in mRNAs encodingsynaptic vesicle proteins, synaptophysin and synaptotagmin I
and IV, and synaptic plasma membrane proteins, SNAP 23 and
SNAP25, whereas an upregulation in mRNA encoding the
plasma membrane protein, syntaxin, was found [57].
There is increasing evidence that certain TRP channels play
critical roles in fundamental synaptic mechanisms. A critical
functional role of agonist-activated TRPC4 channels in the
release of GABA from dendrites has been proposed [58]. It has
also been demonstrated recently that TRPM7 channels are
present in the membrane of cholinergic synaptic vesicles of
sympathetic neurons, form molecular complexes with the
synaptic vesicle proteins, synapsin I and synaptotagmin I, and
directly interact with synaptic vesicular snapin. It was concluded
that TRPM7 channel activity is critical for neurotransmitter
release in sympathetic neurons [59].
Research on the role of TRP channels in synaptic
mechanisms is still at an early stage and it is not possible to
predict the role they might play in schizophrenia. Nevertheless,
recent discoveries of the critical functional roles played by TRP
channels in fundamental mechanisms of neurotransmitter
release indicate that investigation of their possible involvement
in the pathogenesis of schizophrenia is warranted.
3.3. TRP channels and central dopaminergic mechanisms
Of particular relevance to schizophrenia are observations that
TRPV1 channels play a role in dopaminergic mechanisms.
Studies in rat and primate brain have shown that TRPV1
channels are widely expressed throughout the neuroaxis,
including the cortex, hippocampus, basal ganglia, cerebellum
and olfactory bulb as well as in themesencephalon and hindbrain
[47,48]. High expression is found in cell bodies and dendrites of
neurons in the hippocampus and cortex, and also on astrocytes
and pericytes [60]. However, TRPV1 RNA levels in the CNS are
considerably lower than in dorsal root ganglia [61]. Studies on
the distribution of TRPV1 in human brain have been more
restricted. However, TRPV1 receptors have been found in the
third and fifth layers of the human parietal cortex [47].
Until recently, research on TRPV1 channels was predomi-
nantly directed at understanding peripheral sensory mechan-
isms. However, there is growing evidence that TRPV1 channels
have functional roles in the CNS. Furthermore, a potential
endogenous ligand for the TRPV1 receptor, N-oleoyldopamine,
has been found in bovine striatal extracts [62].
In rat brain slices, activation of TRPV1 channels by capsaicin
increased the rate of firing of dopamine neurons of the midbrain
VTA in a concentration dependent manner. The excitation of
dopamine neurons involved a glutamatergic mechanism since it
was blocked by superfusion of ionotropic glutamate antagonists
[63]. Further, in vivo experiments showed that noxious tail
stimulation and microinjection of capsaicin into the VTA
transiently increased dopamine release in the nucleus accum-
bens. Dopamine release by both in vivo tail stimulation and in
vitro application of capsaicin were inhibited by the selective
TRPV1 receptor antagonist, iodoresiniferatoxin, suggesting a
novel role for mesencephalic TRPV1 channels and the dopamine
system following noxious stimulation [63].
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substantia nigra compacta are TRPV1-immunopositive [47,63]
suggested that TRPV1 might be involved in the control of
movement. In support of this suggestion was the observation that
systemic capsaicin suppresses spontaneous locomotion in rats,
an effect which was inhibited by the specific TRPV1 antagonist,
capsazepine [64]. However, the fact that these drugs were given
systemically does not allow firm conclusions to be drawn about
the sites of action of capsaicin in this study.
There is less evidence for a role of other TRP channel
subfamily members in dopaminergic mechanisms. However,
electrophysiological and pharmacological evidence has been
obtained implicating TRPC channels in metabotropic glutamate
receptor 1 (mGluR1)-mediated excitatory post-synaptic cur-
rents (EPSCs) in rat midbrain dopaminergic neurons [65,66].
The results from studies undertaken so far indicate that TRP
channels are likely to play an important role in dopaminergic
mechanisms in the brain and thus their role in schizophrenia
could be of major importance.
3.4. TRP channels and cannabinoid mechanisms
The phylogenetically ancient endocannabinoid system is now
emerging as an important regulator of brain development that
provides pivotal cues to modulate the fate of neural progenitors
[67].
The possible role of cannabis in precipitation of schizo-
phrenia has received considerable attention in recent years.
There is increasing acceptance of an association between
cannabis use and early onset of the first episode of psychosis
in susceptible individuals. The reader is referred to recent
reviews [68–73].
Although there is recognition of an association between
cannabis use and early onset of psychosis, the mechanisms
involved are not clear. Results from recent investigations suggest
complex relationships between TRPV1, cannabinoid and
dopaminergic mechanisms. Heterodimer formation between
CB1 and D2 receptors has been identified as a mechanism of
cross-talk between these two receptor systems [67]. It is not
known whether direct cross-talk occurs between TRPV1
channels and either CB1 or D2 receptors, although indirect
influences via second messenger signaling systems are highly
likely.
The endocannabinoid, anandamide, was initially described as
an endogenous agonist for cannabinoid CB1 receptors, the
predominant cannabinoid receptor in the brain [74]. However,
anandamide also activates TRPV1 channels at an intracellular
site [75] and has been proposed to be an endogenous activator of
TRPV1 channels.
Electrophysiological studies have shown that endocannabi-
noids act as retrograde signaling molecules to modulate
glutamate and GABA mediated regulation of the activity in
midbrain dopaminergic neurons. Activation of both TRPV1 and
CB1 receptors has been shown to modulate dopamine-mediated
locomotion in rats [64]. Interestingly, mice with knockout of the
dopamine transporter (DAT), a useful animal model of the
hyperdopaminergic state, exhibit hyperactivity and have mark-edly reduced anandamide levels in the striatum [76]. Adminis-
tration of indirect endocannabinoids reduced the hyperactivity
by action on TRPV1 receptors and not on CB1 receptors [76].
Immunohistochemical studies have shown a striking simi-
larity between the distribution of TRPV1 and cannabinoid CB1
receptors in many CNS regions, with coexistence occurring in
cell bodies in several regions [77]. TRPV1 and cannabinoid CB1
receptors coexist in the ventrolateral periaqueductal grey (PAG)
neurons of the midbrain, and endocannabinoids may affect
descending pain pathways by acting at either CB1 or TRPV1
receptors [78].
In light of the anatomical and functional overlap between the
TRPV1 and cannabinoid receptor systems, it is tempting to
suggest, despite the limited evidence available, that TRPV1
channels may be implicated in the actions of cannabinoids in
precipitating psychosis, and that ligands for the TRPV1 channels
might provide useful new therapeutic strategies.
3.5. TRP channels and thermoregulation
Subjects with schizophrenia commonly show dysregulation
of body temperature, with abnormal daily body temperature
ranges and an impaired ability to compensate for heat stress,
possibly involving both central and peripheral mechanisms [79–
82]. Although studies in subjects with schizophrenia are often
confounded by neuroleptic drug treatment, disorder of thermo-
regulation has been confirmed in drug-free subjects [80].
The importance of the preoptic area of the anterior
hypothalamus in thermoregulation has been recognized for
many years. Dopamine agonists induce hypothermia in
humans and animals and midbrain dopaminergic mechanisms
have been shown to play an important role in thermoregulation
[83]. Moreover, a complex central regulatory thermostat
mechanism, involving serotoninergic and dopaminergic mech-
anisms, has been described [82]. Evidence for a role of both
dopamine D1 and D2 receptors in the anteroventral preoptic
area has been obtained in rats, dopamine D2 receptors being
mainly involved in the maintenance of body temperature in
euthermia [84].
Injection of capsaicin into the preoptic area also causes
hypothermia in vivo, and capsaicin desensitization induces
impaired ability to thermoregulate against heat [85]. Whilst the
mechanisms are not clear they are likely to be complex involving
both central and peripheral mechanisms. Studies using whole
cell patch-clamp recordings from neurons in the medial preoptic
nucleus have shown that capsaicin enhanced the frequency of
spontaneous glutamatergic excitatory postsynaptic currents and
also of GABAergic inhibitory postsynaptic currents [86].
Injection of capsaicin into the anterior hypothalamus of
knockout mice lacking the TRPV1 channel did not produce a
change in body temperature providing evidence that capsaicin
induces its central effects on thermoregulation via action on
TRPV1 channels [87].
Other TRPV channels are also likely to play a role in thermo-
regulation. Temperature sensitive TRPV3 and TRPV4 channels
are expressed in dopaminergic neurons of the substantia nigra
pars compacta [88]. Indeed, the neuroprotective effect of hypo-
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or TRPV4 channels [89].
The similarity between the thermoregulatory deficit in
animals following capsaicin desensitization and that observed
in schizophrenia is noteworthy. However, the possible inter-
relationships between TRPV channels, dopamine, thermoregu-
lation and schizophrenia remain to be explored.
3.6. TRP channels and sensory processes
Much research on TRP channels is currently focused on their
involvement in sensory processes, particularly in relation to
primary afferent neuron function and nociception. Members of
the TRPM, TRPA and TRPV channel subfamilies activate
sensory mechanisms. Nevertheless, it should be noted that
understanding of the physiological and pathophysiological role
of even the most widely researched TRP, TRPV1, is limited.
3.6.1. TRPM8 and TRPA1 channels
The TRPM8 channel of the TRPM subfamily (melastatin) is
expressed in sensory neurons and is activated by cold, menthol
and icilin and has been proposed to function as a cold
thermosensor [90–93]. The TRPA1 channel, distinguished by
the presence of multiple ankyrin repeats in its N terminus, is also
expressed by sensory neurons. Although first described as a
cold-sensitive, nonselective cation channel [94], studies in
knockout mice have not supported an essential role for TRPA1 in
the detection of noxious cold [95]. TRPA1 is now considered to
function as a ligand-gated channel in sensory neurons, that is
activated by pungent natural compounds including mustard oil,
garlic and cannabinoids, and by endogenous inflammatory
mediators and environmental irritants [95], and inhibited by
menthol [96]. TRPA1 is also regulated by PLC-coupled
receptors, and is possibly the molecular mechanism for the
paradoxical perception of noxious cold as burning pain [97–99].
3.6.2. TRPV channels
Investigation in the field of TRP channels and sensory
mechanisms has been dominated by studies on the role of the
TRPV subfamily in sensory processes.
In the peripheral nervous system TRPV1 channels are
expressed by a class of neuropeptide-containing, unmyelinated
primary afferent neuron involved in nociception, axon reflex
flare and neurogenic inflammation [100,101]. These neurons are
glutamatergic and contact spinal neurons that co-express
tachykinin NK1 receptors and ionotropic (NMDA or AMPA)
glutamate receptors [102]. The TRPV1 channel is considered to
play a key role in nociception and thus research has been driven
by the prospect of development of novel anti-nociceptive or anti-
inflammatory agents [103]. Since its cloning in 1997 [43],
considerable understanding of the amino acids of the TRPV1
protein involved in specific functions such as capsaicin action,
heat activation, proton action, desensitization andmodulation by
lipids, has been gained.
TRPV1 channels are activated polymodally by chemicals
including capsaicin and resiniferatoxin, the endocannabinoid,
anandamide [104], eicosanoids, 2-aminoethoxydiphenyl borate(2-APB) and camphor, as well as by heat, H+ [43,46,105] and
polyamines [106]. Activation results in weakly Ca2+-selective,
outwardly rectifying, cation currents [43]. TRPV1 channels are
sensitized by PKA, PKC, receptor-activated PLC, extracellular
cations and polyamines [106–111]. A novel human TRPV1
RNA splice variant, TRPV1b, which forms functional ion
channels that are activated by noxious temperature but not by
capsaicin or protons, has been reported, and may contribute to
thermal nociception [112].
Genetic influences on variability of human acute experi-
mental pain sensitivity are increasingly being recognized, and
some reports indicate that genetic differences in TRPV1 channel
structure or level of expression might be important. Kim et al.
[113] reported that female European Americans with the TRPV1
Val (585) Val allele showed longer cold withdrawal times. A
human case of decreased expression of TRPV1 resulting in total
loss of sensitivity to capsaicin has been reported [114]. TRPV1
channels have been shown to play an important role in pain
mediated by central sensitization, thus indicating that the role of
TRPV1 channels in pain mechanisms may involve both peri-
pheral and central components [115].
Recently a regulatory protein, Fas-associated factor 1 (FAF1),
that is coexpressed with, and forms an integral component of, the
TRPV1 channel complex, has been found [116]. Silencing FAF1
by RNA interference augments capsaicin-sensitive current in
native sensory neurons and it has been proposed that FAF1
modulates the sensitivity of TRPV1 channels to noxious stimuli
[116]. This finding might explain some of the differences that
have been found between TRPV1 channels and native capsaicin
receptors. Growth factors also play a role in the regulation of
TRPV1 channel function. Neuropeptide release in trigeminal
ganglion neurons in vitro by capsaicin-induced activation of
TRPV1 channels has been shown to be significantly increased by
chronic treatment with nerve growth factor (NGF) and to a lesser
extent by glial cell line-derived neurotrophic factor (GDNF)
[117]. Although the pathophysiological significance of these
modulatory mechanisms has not yet been explored, their
discovery points to a major field of future research.
Activation of TRPV1 channels by vanilloid agonists results in
nociception and neurogenic inflammation mediated primarily by
the neuropeptides, substance P and calcitonin gene related peptide
(CGRP), released from the peripheral terminals of the activated
primary afferent neurons [100,101]. Mice with TRPV1 gene
disruption exhibit loss of responsiveness to capsaicin, protons,
and PKC activation, and deficit in neuropeptide release, but little
change in nocifensive behaviour induced by heat, inflammatory
or neuropathic mechanical hyperalgesia [118,119]. Thus,
although TRPV1 channels are not responsible for normal
nociceptive heat responses, they play an essential role in thermal
hyperalgesia and neuropeptide release, and thus in neurogenic
inflammation.
Desensitization of TRPV1 channels by capsaicin has been
widely exploited in pharmacological investigations into sensory
mechanisms. If given to neonatal rats, capsaicin produces life-
long loss of a high proportion of capsaicin-sensitive primary
afferent neurons [120], the majority of which are unmyelinated
[121]. Desensitization is the major mechanism by which cap-
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induced desensitization of TRPV1 channels is dependent on
extracellular Ca2+, and disruption of binding of the Ca2+-binding
protein, calmodulin, to the C-terminus of the TRPV1 channel
prevents desensitization [122]. PKA reduces TRPV1 desensiti-
zation by phosphorylation of Ser 116 [123], whereas phosphor-
ylation of TRPV1 at S800 by PKCepsilon increases the
sensitivity of desensitized TRPV1 [124].
3.7. Effect of neonatal capsaicin treatment on rat brain
development
The possibility that the somatosensory system might be
involved in the pathogenesis of schizophrenia was suggested by
two observations, firstly, that deficits in pain sensation are
present in subjects with schizophrenia [125,126] and their
relatives [127], and secondly, that vascular responsiveness is
altered as shown by reduced flare responses to niacin (nicotinic
acid) and methylnicotinate in many subjects with the disorder
and their relatives [128,129]. The subset of primary afferent
neurons involved in both pain and flare responses are the small
diameter primary afferent fibres that are sensitive to the
neurotoxic action of capsaicin. These observations suggested
that capsaicin-sensitive primary afferent neurons might be ab-
normal in schizophrenia.
If a population of primary afferent neurons were abnormal in
schizophrenia, the question arises as to how such an abnormality
could give rise to schizophrenia. Studies in developmental
neurobiology have shown that neonatal somatosensory depriva-
tion such as that induced by whisker trimming in the mouse
whisker barrel model, results in reduced synaptic density in the
barrel cortex [130]. The capsaicin-sensitive primary afferent
neurons are widely distributed throughout the body and it might
be expected that even a small deficit in input via these neurons
throughout development could result in reduced synaptic density
in several cortical areas and ‘reduced neuropil’ such as that seen
in the brains of subjects with schizophrenia [15,16].
The possibility that intrinsic somatosensory deprivation affects
brain development was recently tested in rats treated as neonates
with capsaicin to destroy a population of TRPV1-expressing
primary afferent neurons, on the assumption that this would give
rise to an intrinsic somatosensory deprivation [131]. At 5–7
weeks the rats treated as neonates with capsaicin had increased
locomotor activity in a novel environment. Although they had
normal body weight, the male rats had reduced brain weight. The
capsaicin-treated rats also had reduced hippocampal and coronal
cross-sectional area, reduced cortical thickness and increased
neuronal density in several cortical areas [131]. These changes are
similar to those found in schizophrenia. The brain changes were
maintained into adulthood (11–12 weeks), indicating that
neonatal capsaicin treatment produced long-lasting changes in
the rat brain (Newson et al. unpublished). Furthermore, cutaneous
inflammatory responses to methylnicotinate were reduced in
capsaicin-treated rats, showing that the response to methylnico-
tinate had a neurogenic component (Newson et al. unpublished).
The findings of Newson et al. [131] suggest that the neonatal
capsaicin-treated rat might be a useful animal model of schizo-phrenia. However, the study was based on the assumption that
the principle site of action of capsaicin was the TRPV1 channel
on the primary afferent neuron. Although the primary afferent
neuron would undoubtedly have been a major target of neonatal
capsaicin treatment in this study, the possibility that capsaicin
produced the observed brain changes by actions in the CNSmust
be considered. A neurotoxic action of capsaicin on central
TRPV1 channels, similar to that observed in the peripheral
sensory system, was considered unlikely as neonatal capsaicin
treatment has been shown not to affect TRPV1 receptor mRNA
expression in rat brain [47]. However, action on target molecules
other than TRPV1 channels might have occurred. A difficulty
with the use of capsaicin as a tool, is its widespread action on
membrane proteins other than TRPV1 channels such as voltage-
dependent sodium channels. Capsaicin and the capsaicin
antagonist, capsazepine have been shown to regulate these
proteins by altering lipid bilayer elasticity [132].
Older studies had shown that the neurotoxic effect of
capsaicin is not limited to somatosensory neurons. Although
other neurons in the periphery, such as lower motor neurons,
were not affected, Perez et al. [133] showed that olfactory
afferents were sensitive to the neurotoxic effects of neonatal
capsaicin treatment, and that body, brain and olfactory bulb
weights were reduced in capsaicin-treated rats. Furthermore, a
study of the effects of systemic capsaicin on the CNS of 10-day-
old and adult rats showed that many areas not previously known
to receive primary afferent input, including the interpeduncular
nucleus, raphe nuclei, hypothalamic and septal nuclei, accum-
bens shell and olfactory bulb, showed evidence of degenerating
terminals [134,135]. The long-term functional significance of
this effect is unknown as several of these CNS areas are not
responsive to capsaicin in the adult rat [135]. Indeed, some of
these degenerative effects might have resulted directly or
indirectly from degeneration of vagal sensory neurons [134].
Studies on the effects of capsaicin in adult rats have shown
that capsaicin does not affect the permeability of the blood–brain
barrier [136], and that capsaicin causes degeneration of central
terminals of primary afferent neurons in the adult CNS only
when applied centrally [137]. However, in neonatal rats the
blood–brain barrier is more permeable and it is likely that
capsaicin would enter the brain and have CNS actions. Whether
these actions have long-term consequences for brain develop-
ment and function remains to be determined.
Despite the limitations of the study by Newson et al. [131],
the simplest explanation for the findings is that neonatal cap-
saicin treatment resulted in somatosensory deprivation which
affected brain development. Further studies are required to
determine whether the changes produced in rat brain by neonatal
capsaicin treatment result from somatosensory deprivation or
direct actions of capsaicin within the brain. Such information
will be required before the neonatal capsaicin-treated rat is
accepted as a useful animal model of schizophrenia.
4. Conclusion
Schizophrenia remains amajor challenge to neuroscience and
to pharmacotherapeutics. The affliction of the unique human
974 L.A. Chahl / Biochimica et Biophysica Acta 1772 (2007) 968–977higher nervous system has resulted in lack of validated animal
models [138] and has hindered rational drug development.
Recognition of the probable polygenic nature of schizophrenia
and the role of environmental factors has not yet led to greater
understanding of the fundamental pathophysiology of schizo-
phrenia. The discovery of neuropathological changes in many
brain regions and of changes in several neurotransmitter systems
has also not clarified the aetiology of the disorder. The number of
brain changes that have been described makes it tempting to
speculate that the cause of schizophrenia is a subtle abnormality
in a fundamental cellular process, such as TRP channel
signaling, that results in many consequent neurochemical and
epigenetic changes. On current evidence it seems unlikely that a
single gene disruption in a TRP channel would be directly
responsible. Nevertheless, the possibility remains that an
environmental factor might precipitate disruption or silencing
of a single gene such as a TRP channel gene, hitherto
unsuspected of involvement in schizophrenia, with downstream
neurodevelopmental and neurochemical consequences resulting
in the disorder. Studies on mice deficient in likely TRP channel
candidates such as TRPV1 channels, have so far concentrated on
the peripheral sensory deficits [139]. Further exploration of the
effects of TRP channel deficiencies on the brain and behaviour
are warranted.
Study of the role of TRP channels is still at an early stage and
few firm conclusions can be reached about their possible role in
a disorder as complex and poorly understood as schizophrenia.
Nevertheless, the possible links between TRP channels,
neurodevelopment and the neurochemical and pathophysiolo-
gical mechanisms involved in schizophrenia, are tantalizing,
and give rise to the prospect that investigation of these links
might yield a new understanding of schizophrenia and brain
mechanisms in general with resultant therapeutic advances.References
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